Zai Lab : Full Year 2022 Financial Results and Corporate Update Presentation

FY 2022

Financial Results & Corporate Updates

March 2, 2023

Zai Lab Forward-Looking Statements

These slides contain forward-looking statements relating to our strategy and plans; potential of and expectations for our business and pipeline programs; capital allocation and investment strategy; clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities; our future financial and operating results; and financial guidance. All statements, other than statements of historical fact, included in these slides are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe,"

"could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements

constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business initiatives; (3) the results of our clinical and pre-clinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates; (5) the effects of the COVID-19 pandemic on our business and results of operations; (6) risks related to doing business in China; and (7) other factors identified in our most recent annual report filed with the U.S. Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of these slides being presented.

Our SEC filings can be found on our website at www.zailaboratory.comand on the SEC's website at www.SEC.gov.

2

Agenda

• Full-Year2022 Financial Results and Corporate Updates
• 2023 Anticipated Milestones
• Q&A

Samantha Du, Ph.D.	Josh Smiley	Rafael Amado, M.D.	Harald Reinhart, M.D.	Billy Cho
Founder, Chairperson and	Chief Operating	President, Head of Global	President, Head of	Chief Financial Officer
Chief Executive Officer	Officer	Oncology Research and	Global Development,
		Development	Neuroscience, Autoimmune
			and Infectious Diseases

3

Samantha Du, Ph.D.

Founder, Chairperson and Chief

Executive Officer

4

2022: Another Year of Strong Execution and Delivery on Our Commitments

Strong Commercial Execution

• Four marketed products with substantial growth
• ZEJULA reached 39% of total
  PARP hospital sales in 4Q'22 in
  China

Numerous Positive/ Pivotal Data Readouts

• E.g., Efgartigimod, KarXT, TTFields, and Adagrasib

Global Clinical Development

• E.g, TTFields LUNAR, Repotrectinib TRIDENT-1

Key Regulatory Events

• QINLOCK and NUZYRA on NRDL

Strategic Partnership

Seagen Collaboration

Strengthened Global

Leadership Team

• Josh Smiley, COO
• Rafael Amado, MD, President, Head of Global Oncology R&D
• Peter Huang, PhD, CSO

5